Advertisement
U.S. markets open in 6 hours 29 minutes

Assembly Biosciences, Inc. (ASMB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.58+0.24 (+2.12%)
At close: 04:00PM EST
11.15 -0.43 (-3.71%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close11.34
Open11.32
Bid0.00 x 3200
Ask0.00 x 900
Day's Range11.16 - 11.63
52 Week Range7.68 - 20.04
Volume25,666
Avg. Volume31,502
Market Cap63.491M
Beta (5Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-17.16
Earnings DateMar 20, 2024 - Mar 25, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ASMB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Assembly Biosciences, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
    Rating
    Fair Value
    Economic Moat
    4 months agoMorningstar
View more
  • GlobeNewswire

    Assembly Biosciences Announces Effective Date of Reverse Stock Split

    – Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024. The company anticipates that its common s

  • Simply Wall St.

    This Assembly Biosciences Insider Increased Their Holding In The Last Year

    Looking at Assembly Biosciences, Inc.'s ( NASDAQ:ASMB ) insider transactions over the last year, we can see that...

  • GlobeNewswire

    Assembly Biosciences Provides Anticipated Development Milestones for 2024

    Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D virusesInitial clinical data anticipated by end of year from first-in-human study of long-acting helicase-primase inhibitor targeting recurrent genital herpes (ABI-5366) and Phase 1b study of next-generation core inhibitor for chronic hepatitis B virus (ABI-4334)Recently announced long-term partnership with Gilead Sciences, Inc. (Gilead)